Reports as of December 31, Cash totaled $48.5M, compared to $98.5M for the year ended December 31, 2022..”We have kicked off 2024 with positive momentum announcing positive topline results from our Phase 1 study for RT-111, which serves as our third successfully completed Phase 1 trial using RaniPill technology,” said Talat Imran, Chief Executive Officer of Rani. “The results of our Phase 1 study for RT-111 provide validation that our platform can transform injectable large molecules into convenient, oral pills. We are committed to our vision of making oral biologics a reality across a wide variety of indications. Looking ahead, we continue development of the RaniPill HC to be ready for potential Phase 1 clinical trials in the second half of the year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RANI:
- Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
- RANI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
- Rani Therapeutics Reports Positive Phase 1 Trial Outcomes
- Rani Therapeutics Shares Exciting Clinical Trial Results